Post-pandemic recovery stocks run out of puff
The Covid-19 vaccines have been successful. Many plays on the global recovery have not done so well.
On 9 November 2020, Pfizer and BioNTech announced that their vaccine for Covid-19 was more effective than almost anybody had hoped, with more than 90% protection against the virus. The news sparked a strong rally in global stockmarkets. Many sectors such as airlines and retail that had been crushed by the closure of the global economy surged on hopes that the world would return to normal, as did broader groupings such as emerging markets and value stocks.
One year on, the Pfizer/BioNTech vaccine and others have met all reasonable expectations. The world has partially reopened, even if a lot of government policies remain clearly irrational and panicky. Yet the outcome for markets hasn’t been as expected. Some much-touted bets have turned out poorly, while some huge returns have come from stocks that were supposed to fall out of favour.
Growth is beating value
We can certainly see plenty of big winners from reopening, especially in retail and leisure. In the UK, bakery chain Greggs and transport operator FirstGroup have both gained over 100%, as has Saga, which offers tours and cruises. But the MSCI World Value index returned 29% in sterling terms over the year, compared to 26% for the MSCI World Growth – a modest difference and one that vanishes if your starting point is one day later. And in recent months, growth has come back more strongly.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Sectors such as airlines have done poorly on the whole, up 20% compared with more than 40% for technology. Some of the stay-at-home/work-from-home plays have fallen (eg, online fitness firm Peloton), but many of the tech heavyweights have kept soaring: Microsoft is up 60% and Alphabet up 70%. I’m personally relieved by both of those, because they have helped offset many of the emerging markets in my portfolio: the MSCI Emerging Markets index is up just 5% compared with 27% for the MSCI World.
There are obvious reasons for some of these disappointments. Travel restrictions continue to hold back airlines and are taking longer to remove than expected. Emerging markets have suffered from a slow vaccine roll-out, the loss of tourism and the many economic consequences of the pandemic. Some such as India, Russia and Vietnam have done well, but others such as Brazil are still suffering. Supply-chain bottlenecks, rising labour costs, and higher energy prices play a part, although many of these bring winners as well as losers: energy is up almost 60% over the year.
However, the broader lesson is that investors would rather bet on growth in these uncertain times, no matter how cheap value looks. With plenty of worries for the winter months ahead, there isn’t an obvious catalyst to change that.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Cris Sholto Heaton is an investment analyst and writer who has been contributing to MoneyWeek since 2006 and was managing editor of the magazine between 2016 and 2018. He is especially interested in international investing, believing many investors still focus too much on their home markets and that it pays to take advantage of all the opportunities the world offers. He often writes about Asian equities, international income and global asset allocation.
Cris began his career in financial services consultancy at PwC and Lane Clark & Peacock, before an abrupt change of direction into oil, gas and energy at Petroleum Economist and Platts and subsequently into investment research and writing. In addition to his articles for MoneyWeek, he also works with a number of asset managers, consultancies and financial information providers.
He holds the Chartered Financial Analyst designation and the Investment Management Certificate, as well as degrees in finance and mathematics. He has also studied acting, film-making and photography, and strongly suspects that an awareness of what makes a compelling story is just as important for understanding markets as any amount of qualifications.
-
Pension warning: one in five don’t know how much is going into their pension
How to check your pension contributions and why it matters
By Katie Williams Published
-
50,000 power of attorney applications rejected – how to avoid common mistakes
A freedom of information request shows that thousands of lasting power of attorney (LPA) applications are rejected due to errors. We explain how to avoid mistakes and reveal tips to make the process as straightforward as possible
By Ruth Emery Published
-
Investing in a dangerous world: key takeaways from the MoneyWeek Summit
If you couldn’t get a ticket to MoneyWeek’s summit, here’s an overview of what you missed
By MoneyWeek Published
-
DCC: a top-notch company going cheap
DCC has a stellar long-term record and promising prospects. It has been unfairly marked down
By Jamie Ward Published
-
How investors can use options to navigate a turbulent world
Explainer Options can be a useful solution for investors to protect and grow their wealth in volatile times.
By James Proudlock Published
-
Invest in Hilton Foods: a tasty UK food supplier
Hilton Foods is a keenly priced opportunity in an unglamorous sector
By Dr Matthew Partridge Published
-
HSBC stocks jump – is its cost-cutting plan already paying off?
HSBC's reorganisation has left questions unanswered, but otherwise the banking sector is in robust health
By Dr Matthew Partridge Published
-
Lock in an 11% yield with Sabre
Tips Sabre, a best-in-class company is undervalued due to low profits in the motor insurance industry. Should you invest?
By Rupert Hargreaves Published
-
James Halstead is a family firm going cheap but should you buy?
James Halstead will rebound from a weak patch, while tax changes would be a buying opportunity
By Jamie Ward Published
-
The Gulf states: a new competitor for the City's financial crown?
Bahrain and other Gulf states could eventually threaten London's financial dominance.
By Matthew Lynn Published